ReviewClinics in laboratory medicine2019
Biomarkers for Early Complications After Hematopoietic Stem Cell Transplantation.
Review in Clinics in laboratory medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 16 citations in OpenAlex.
- ST2 and Reg3α: Can they predict aGvHD, steroid refractoriness and transplant-related mortality in pediatric patients after HSCT?Hematology, transfusion and cell therapy · 2024Article
- Biomarkers to predict and diagnose pulmonary complications in children post haematopoietic stem cell transplant.Clinical & translational immunology · 2024Review
- Antigen-specific T cell responses correlate with decreased occurrence of acute GVHD in a multicenter contemporary cohort.Bone marrow transplantation · 2022Article
- Article
- Article
- Autoimmunity Following Allogeneic Hematopoietic Stem Cell Transplantation.Frontiers in immunology · 2020Review
- Association of Serum Ferritin Levels Before Start of Conditioning With Mortality After alloSCT - A Prospective, Non-interventional Study of the EBMT Transplant Complications Working Party.Frontiers in immunology · 2020Article
- Biomarkers for Allogeneic HCT Outcomes.Frontiers in immunology · 2020Review
- A T-Cell Surface Marker Panel Predicts Murine Acute Graft-Versus-Host Disease.Frontiers in immunology · 2020Article
- Pharmacological Applications of Nrf2 Inhibitors as Potential Antineoplastic Drugs.International journal of molecular sciences · 2019Review
- Immune Reconstitution Disorders: Spotlight on Interferons.International journal of biomedical investigation · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Advances in the field of omics have led to a significant expansion in biomarkers identified for complications after hematopoietic stem cell transplantation (HSCT). Biomarkers can offer an effective method for early identification of a specific disease and can be used to guide therapies. Ongoing investigations to discover biomarkers for acute graft-versus-host disease as well as other post-HSCT complications may improve early diagnosis, prognosis, and the development of new therapeutic targets. The authors review the most recent and validated diagnostic, prognostic, predictive, and response to treatment biomarkers for early complications following HSCT consistent with 2014 NIH consensus on biomarker criteria.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.